• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Linezo-avenir
    / BioAvenir Ltd.


    Active Ingredient
    Linezolid 600 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    1 x 600 mg

    not in the basket chart

    Film Coated Tablets

    10 x 600 mg

    not in the basket chart

    Film Coated Tablets

    20 x 600 mg

    not in the basket chart

    Film Coated Tablets

    30 x 600 mg

    not in the basket chart

    Film Coated Tablets

    50 x 600 mg

    not in the basket chart

    Film Coated Tablets

    60 x 600 mg

    not in the basket chart

    Film Coated Tablets

    100 x 600 mg

    not in the basket chart

    Film Coated Tablets

    200 x 600 mg

    not in the basket chart

    Related information


    Dosage

    The dosage and treatment regimen is depended on indication. linezolid dosage should be administered orally twice daily. Please refer to the license holder for further details.


    Indications

    Therapy is indicated only when an organism resistant to all other antibiotics is suspected.
    This medicinal product is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as:
    1) Pneumonia – community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (MDRSP).
    2) Skin and soft tissue infections including diabetic foot infections.
    3) Enterococcal infections.
    Combination therapy may be indicated if a concomitant Gram-negative pathogen is documented or suspected.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients.
    Breastfeeding.
    Patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid, selegiline, moclobemide) or within two weeks of taking any such medicinal product.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Please refer to the license holder for further details.


    Drug interactions

    Please refer to the license holder for further details.


    Pregnancy and Lactation

    Please refer to the license holder for further details.


    Overdose

    Please refer to the license holder for further details.


    Manufacturer
    Hetero labs limited, India
    Licence holder
    CLOSE